Form 4: Esperion Therapeutics Officer Joanne M. Foody Reports Sale of Shares for Tax Obligations

Joanne M. Foody, Chief Medical Officer of Esperion Therapeutics, sold 917 shares of common stock on July 17, 2024, to cover tax obligations arising from vested restricted stock units.

Summary

• On July 17, 2024, Joanne M. Foody, the Chief Medical Officer of Esperion Therapeutics, Inc., sold 917 shares of the company's common stock.
• The sale was executed at a price of $2.599 per share.
• The transaction was conducted to satisfy tax obligations related to vested shares of restricted stock units.
• Following the transaction, Foody directly owns 272,862 shares of Esperion Therapeutics, Inc.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a stock sale by an officer to cover tax obligations. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Industry Context

This is a routine Form 4 filing, indicating an insider transaction. Such filings are common and provide transparency into the trading activities of company officers and directors. The sale appears to be related to tax obligations, which is a typical reason for such transactions.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
• Similar filings are made by officers and directors at companies like Amgen, Regeneron, and Novartis when they engage in transactions involving their company's stock.
• The number of shares sold and the reasons for the sale (e.g., tax obligations) are consistent with typical insider transactions observed across the pharmaceutical industry.

Stakeholder Impact

• The sale of shares by an officer could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale (tax obligations).

Key Dates